Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00778661 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00778661: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT00778661 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00778661, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and GlaxoSmithKline (Augmentin®) 400 mg amoxicillin (as the trihydrate) and 57 mg clavulnic acid (as the potassium salt) chewable tablet, following administration of 2 tablet dose under fasting conditions
Interventions
- DRUG amoxicillin 400mg + clovalunic acid 57.5mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-10 |
| Est. Completion | 2002-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00778661
The ClinicalTrials.gov registry entry for NCT00778661 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which amoxicillin 400mg + clovalunic acid 57.5mg tablets is the first listed.
NCT00778661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00778661 about?
NCT00778661 is a clinical study titled "Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions". The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and GlaxoSmithKline (Augmentin®) 400 mg amoxicillin (as the trihydrate) and 57 mg clavulnic acid (as the potassium salt) chewable tablet, following administration of 2 tablet dose under fasting conditions
What is the current status of trial NCT00778661?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2002-10. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00778661?
The interventions under investigation include: amoxicillin 400mg + clovalunic acid 57.5mg tablets (DRUG).
Who is sponsoring clinical trial NCT00778661?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.